Table 5 Linear regression analysis of total follow-up
Regression coefficient | 95% confidence interval | p value | |
|---|---|---|---|
Intercept | 20.21 | (15.31; 25.11) | < 0.001 |
FDDP use (vs. conventional follow-up) | − 0.63 | (− 2.22; 0.96) | 0.439 |
Female gender (vs. male) | − 0.82 | (− 2.27; 0.64) | 0.273 |
Age (per year) | 0.03 | (− 0.02; 0.08) | 0.261 |
Concomitant cardiac disease | 1.41 | (− 0.46; 3.27) | 0.141 |
Physician experience in clinical EP (per year) | − 1.07 | (− 1.39; -0.75) | < 0.001 |
Device type | 0.009 | ||
Single chamber P (vs. CRT-P/CRT-D) | − 2.77 | (− 5.83; 0.28) | * |
Dual chamber P (vs. CRT-P/CRT-D) | − 1.84 | (− 4.11; 0.43) | * |
Single chamber ICD (vs. CRT-P/CRT-D) | − 3.49 | (− 5.67; − 1.32) | * |
Dual chamber ICD (vs. CRT-P/CRT-D) | 0.06 | (− 2.94; 3.06) | * |
Device manufacturer | 0.243 | ||
Boston Scientific (vs. Medtronic) | 1.59 | (− 0.62; 3.81) | * |
Biotronik, LivaNova (Ela/Sorin), Vitatron (vs. Medtronic) | 1.20 | (− 1.18; 3.59) | * |
St. Jude Medical (vs. Medtronic) | − 0.67 | (− 2.48; 1.15) | * |